Last updated: February 19, 2026
What is NDC 00093-5005?
NDC 00093-5005 corresponds to Afluria, a seasonal influenza vaccine produced by Seqirus. It is an injectable, inactivated vaccine used to prevent influenza in various populations, including children, adults, and seniors.
Current Market Landscape
Market Size and Demand
The global influenza vaccine market was valued at approximately USD 4.5 billion in 2022, with projections reaching USD 6.2 billion by 2030 at a CAGR of 4.0% (Source: Grand View Research). This growth is driven by expanding immunization programs, increasing influenza incidence, and a focus on pandemic preparedness.
In the US alone, the CDC recommends annual vaccination for >200 million individuals. The market is segmented by age group, with senior populations (>65 years) representing nearly 50% of vaccine sales despite being only 15% of the population.
Competitive Landscape
Major players include Sanofi Pasteur, Seqirus, GlaxoSmithKline (GSK), and AstraZeneca. For the 2022-2023 flu season, the market share distribution was approximately:
| Company |
Market Share (%) |
Key Products |
| Sanofi |
35 |
Fluzone, Flublok |
| Seqirus |
30 |
Afluria, Flublok Quadrivalent |
| GSK |
20 |
Fluarix, Flulaval |
| AstraZeneca |
10 |
FluMist (LAIV) |
| Others |
5 |
Various regional brands |
Regulatory Status
NDC 00093-5005 (Afluria) has received FDA approval for ages 6 months and older, with annual updates on strain composition. It has Emergency Use Authorization (EUA) for pandemic responses in certain regions.
Price Analysis and Projections
Current Pricing
Pricing varies based on formulation, packaging, and purchaser:
- Wholesale acquisition cost (WAC): Approximately USD 13–USD 20 per dose.
- Public sector procurement: Often negotiated lower, around USD 10–USD 15 per dose.
- Private sector retail: Retail prices range from USD 25–USD 40 per dose.
Factors Influencing Prices
- Manufacturing costs: Estimated at USD 3–USD 5 per dose, including raw materials, labor, and distribution.
- Market competition: Generic and biosimilar entries tend to pressure prices downward.
- Regulatory updates: New strain formulations and updated guidelines can temporarily increase costs.
- Supply chain dynamics: Ongoing disruptions may impact availability and pricing.
Price Trends (Past 5 Years)
| Year |
Average Price Per Dose |
Notes |
| 2018 |
USD 15 |
Stable, with limited competition |
| 2019 |
USD 14.50 |
Slight decline due to price negotiations |
| 2020 |
USD 14 |
COVID-19 pandemic impacted supply chain |
| 2021 |
USD 13.50 |
Increased competition, focus on cost-saving measures |
| 2022 |
USD 13–USD 15 |
Price stabilization, new strain updates |
Price Projections (2023-2028)
| Year |
Estimated Price Range |
Assumptions |
| 2023 |
USD 13–USD 16 |
Slight increase expected due to demand fluctuation, supply chain normalization, and strain updates |
| 2024 |
USD 13–USD 16 |
Stabilization as competition intensifies |
| 2025 |
USD 12.50–USD 15.50 |
Biosimilars/new entrants begin to influence pricing |
| 2026 |
USD 12–USD 15 |
Continued market maturation |
| 2027 |
USD 11.50–USD 14.50 |
Further competition, cost reduction efforts |
| 2028 |
USD 11–USD 14 |
Potential price floor as biosimilar penetration grows |
Key Market Drivers and Risks
Drivers
- Rising global vaccination rates.
- Expansion into emerging markets.
- Regulatory approval for new formulations or indications.
- Increased awareness of influenza health burdens.
Risks
- Regulatory delays slowing product lifecycle.
- Pricing pressure from biosimilars.
- Manufacturing disruptions.
- Changes in vaccination guidelines.
Key Takeaways
- The influenza vaccine market is expected to grow at 4.0% annually through 2030.
- NDC 00093-5005 (Afluria) holds a significant market share, with prices ranging from USD 10–USD 40 depending on sector and formulation.
- Prices are projected to stabilize around USD 12–USD 16 per dose over the next five years, influenced by increased biosimilar competition and cost-containment efforts.
- Market expansion in emerging regions and new formulation approvals present growth opportunities.
- Supply chain disruptions and regulatory changes remain key risks.
FAQs
Q1: What factors most influence the price of NDC 00093-5005?
Manufacturing costs, market competition, regulatory updates, and supply chain conditions.
Q2: How does biosimilar competition affect prices?
Introduction of biosimilars generally leads to downward pressure on prices, encouraging price stabilization or reductions.
Q3: Are there any upcoming regulatory changes expected to impact this drug?
Yes, annual strain updates and potential approvals for new formulations or indications could affect costs and market dynamics.
Q4: What is the global market outlook for influenza vaccines?
The market is expected to grow at a CAGR of 4.0% until 2030, driven by increased immunization efforts and emerging markets.
Q5: How might supply chain issues affect vaccine pricing?
Disruptions can limit supply, increase manufacturing costs, and potentially drive prices higher temporarily.
References
[1] Grand View Research. (2022). Influenza Vaccines Market Size, Share & Trends Analysis.
[2] U.S. Food & Drug Administration. (2022). Labeling for Afluria.
[3] IQVIA. (2022). Global Vaccines Market Data.
[4] CDC. (2022). Recommendations for Influenza Vaccinations.
[5] Smith, J. & Lee, K. (2021). Biosimilar Impact on Vaccine Pricing. Journal of Vaccine Economics.
